Clinical Trials
41 trialspanSOHO
Bayer
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
DP-04
AstraZeneca
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
National Institutes of Health Clinical Center (CC)
Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
University of California, San Diego
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
GlaxoSmithKline
PEMIGIST
Dana-Farber Cancer Institute
A Novel Two-Tooth Clip for ESD and EFTR of GIST
Affiliated Hospital to Academy of Military Medical Sciences
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting
Kumquat Biosciences Inc.
iCaRe2
University of Nebraska
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
Peking University Cancer Hospital & Institute
ATEZOGIST
Centre Leon Berard
Long-term Survivorship Challenges of Advanced/Metastatic GIST Patients Responding to Tyrosine Kinase Inhibitor Treatment: an Observational Study
The Netherlands Cancer Institute
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Ascentage Pharma Group Inc.
GIST
Asan Medical Center
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
Asan Medical Center
GIST Oral Paclitaxel(Liporaxel)
Asan Medical Center
SUR-CAN
Centre Oscar Lambret
Imatinib TDM in GIST
University of Kentucky
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
Deciphera Pharmaceuticals, LLC
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Kura Oncology, Inc.
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
Stanford University
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility, Inc.
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
University of Miami
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Asan Medical Center
Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis
Huazhong University of Science and Technology
PARTNER
Azienda Ospedaliera di Padova
Observational Registry Data on GIST Patients
National Health Research Institutes, Taiwan
Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery
Chinese University of Hong Kong
(SELNET)
Grupo Espanol de Investigacion en Sarcomas
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA
First Affiliated Hospital, Sun Yat-Sen University
A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors
First Affiliated Hospital, Sun Yat-Sen University
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Universidad Nacional Autonoma de Mexico
Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST
First Affiliated Hospital of Chongqing Medical University
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
Centre Leon Berard
A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors
Fujian Medical University
Clinical Research of Drug Holiday Based on MRD Detection in GIST Patients at High Risk of Recurrence
Peking University People's Hospital
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
Xiangya Hospital of Central South University
Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD
Peking University People's Hospital
ZJGIST-01
First Affiliated Hospital of Zhejiang University